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The recent identiﬁcation of metastasis suppressor genes, the products of which inhibit metastasis
but not primary tumor growth, distinguishes oncogenic transformation and tumor suppression
from a hallmark of malignancy, the ability of cancer cells to invade sites distant from the primary
tumor. The metastasis suppressor CD82/KAI1 is a member of the tetraspanin superfamily of glyco-
proteins. CD82 suppresses metastasis by multiple mechanisms including inhibition of cell motility
and invasion, promotion of cell polarity as well as induction of senescence and apoptosis in
response to extracellular stimuli. A common feature of these diverse effects is CD82 regulation of
membrane organization as well as protein trafﬁcking and interactions, which affects cellular signal-
ing and intercellular communication.
Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction 2. CD82 as a metastasis suppressor geneMetastasis remains by far the major cause of cancer-related
mortality. This multi-step process has, as a ﬁrst common initial
feature, the movement of malignant cells from the primary tumor.
This is followed by their entry into the circulation and their suc-
cessful traversal of the circulation to a distant site where, after
exiting the circulation, they establish themselves and proliferate
to form overt metastases. An improved understanding of the de-
tails that allow for the completion of these multiple steps, and
the molecular mechanisms by which they are naturally prevented,
should lead to new approaches to cancer treatment. In the past
decades, the discovery of genes that speciﬁcally suppress metasta-
sis has offered new insights into the process of metastasis. The
observation that metastasis suppressors exert little effect on pri-
mary tumor growth suggests that these gene products either di-
rectly or indirectly inﬂuence the interactions of the tumor cells
with their microenvironments. Metastasis suppressor genes that
interrupt different steps of the metastatic cascade have been de-
scribed (see accompanying articles this issue). Herein, we discuss
the functions of CD82/KAI1, focusing on its roles in regulating pro-
tein and membrane dynamics.lf of the Federation of European Bi
tein Dynamics and Signaling,
, 1050 Boyles Street, Building
.The metastasis suppressor gene KAI1 (Kangai1), located on
chromosome 11p11.2, was originally identiﬁed in a screen for
genes on chromosome 11 that suppressed metastasis of rat AT6.1
prostate cancer cells. Re-expression of KAI1 in AT6.1 reduced the
formation of metastases without affecting primary tumor growth
[1]. KAI1 was previously described as CD82, a lymphocyte cell sur-
face protein involved in activation of T cell receptor [2]. CD82 is
also known as antigens R2, C33, IA4 and 4F9 [3–6]. Subsequent
studies conﬁrmed the metastasis suppressor function of CD82 in
hepatocarcinoma, melanoma, sarcoma, pancreatic and breast can-
cer cell lines [7–11]. The importance of CD82 in cancer progression
is underscored by the observation that downregulation of CD82
mRNA and protein is associated with advanced stages of many
malignancies (reviewed in [12]) including prostate, colon, lung,
pancreatic, breast, ovarian and other cancers.
CD82 is a member of the tetraspanin superfamily of glycopro-
teins. Tetraspanins are characterized by four transmembrane do-
mains with conserved polar residues, which may help to stabilize
a tight tertiary structure [13–15] (Fig. 1). They have short intracel-
lular N- and C-termini, one short (ECL1) and one long (ECL2) extra-
cellular hydrophilic loops and a very short intracellular loop. The
intracellular juxtamembrane cysteines are usually modiﬁed by
palmitoylation, which contributes to the formation of a tetraspanin
web with other tetraspanins as well as non-tetraspanin proteins.
Based on a modeled structure of CD81, a related tetraspanin, the
N terminus likely forms a membrane-parallel amphipathic helixochemical Societies.
Fig. 1. Schematic of CD82 structure. CD82 has four transmembrane domains with conserved polar residues (light blue), which may be important for structural integrity. The
long extracellular loop (ECL2) contains six cysteine residues (yellow) predicted to form three disulﬁde bonds (magenta). The glycine residue in the characteristic Cys-Cys-Gly
motif is highlighted in red. ECL2 also contains three asparagine (green) residues that are sites for N-linked glycosylation. Juxtamembrane cysteine residues (yellow) are
usually palmitoylated. Palmitoylation of the N-terminal cysteine likely holds the N-terminus parallel to the membrane. The C-terminus contains a sorting motif (orange)
important for localization to the endocytic pathway.
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dom structure [13]. The short ECL1 appears to possess a b-strand
that is enriched with hydrophobic residues and may interact with
the hydrophobic groove of ECL2 [13]. ECL2 is the most variable re-
gion among the tetraspanins and provide antigenic speciﬁcity as
most monoclonal antibodies map to this region. ECL2 also contains
the signature Cys-Cys-Gly motif, which forms two disulﬁde bonds
with two other conserved cysteines in ECL2. ECL2 can be divided
into a constant region and a variable region: the constant region
may contribute to oligomerization with other tetraspanins while
the variable region may contribute to interactions with other
non-tetraspanin proteins [13,16]. ECL2 of CD82 contains three con-
sensus N-linked glycosylation sites. When overexpressed, CD82
sometimes show a wide range of molecular weights on SDS–PAGE
(40–90 kDa) due to varying degrees of glycosylation. Glycosylation
of tetraspanins is important not only for their transit through the
endoplasmic reticulum (ER) during maturation but also for com-
plex formation and cellular functions [15,17,18].
Tetraspanins form large multimeric complexes that consist of
tetraspanins as well as other membrane and cytosolic proteins
such as receptor tyrosine kinases, integrins, and adaptor proteins
that are integral to signaling cascades. They are also enriched for
speciﬁc lipids including gangliosides. These complexes are clus-
tered in specialized membrane domains known as ‘‘tetraspanins-
enriched microdomains’’ (TEM). CD82 does not have any evident
enzymatic activity. As discussed in the following sections, CD82
seems to instead function by modulating the levels, trafﬁcking or
activity of its interacting partners in the TEM.3. Mechanisms of CD82 function
Unlike other metastasis suppressors, CD82 appears to inhibit
multiple steps of the metastatic cascade including cell motility
and invasion, proliferation, apoptosis and senescence. CD82 has
an impact on the interaction of tumor cells with their microenvi-
ronments in ways that are non-permissive for survival and prolif-
eration beyond the primary tumor. This broad range of effects can
be achieved by the modulation of the activity and trafﬁcking of
proteins critical for metastasis through physical or functional
interactions with CD82.
3.1. Cell–cell adhesion
One important function of CD82 is to promote homotypic
cell–cell adhesion. Loss of cell adhesion plays an important role
in epithelial–mesenchymal transition (EMT) and metastasis. In
DU145 cells, transfection of CD82 induces homotypic cell–cell
aggregation. This increase in cell–cell adhesion can be blocked
with protein phosphatase 1, an inhibitor of Src kinase, or by
overexpression of a kinase defective Src mutant [19], implicating
activation of Src-mediated pathways in CD82-mediated effects.
In non-small cell lung carcinoma, overexpression of CD82 pro-
motes cell–cell adhesion [20], which depend on E-cadherin.
CD82 does not alter the distribution of E-cadherin in these cells;
instead, CD82 stabilizes E-cadherin/b-catenin complex formation,
which can inhibit cancer cell dissemination from the primary
tumor.
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In vitro studies show that overexpression of CD82 inhibits cell
motility and invasion [11,14,15,21–27]. The association of CD82
with a6 integrin results in decreased laminin adhesion and migra-
tion [28]. Integrins mediate cell adhesion to the extracellular ma-
trix by binding matrix ligands such as laminin and ﬁbronectin.
CD82 downregulates a6 integrin by increasing its internalization
resulting in reduced laminin adhesion. In H1299 lung carcinoma
cells, CD82 reduces cell surface expression of b1 integrin by inter-
fering with the b1 integrin glycosylation and maturation [24].
CD82 also associates with EWI-2/PGRL, a transmembrane immu-
noglobulin G superfamily protein [29]. Overexpression of EWI-2
in DU145 metastatic prostate cancer cells inhibits cell migration
on both ﬁbronectin- and laminin-coated substrata, indicating that
EWI-2 directly regulates cell migration. The association of CD82
with EWI-2 enhances CD82 inhibition of cancer cell motility, sug-
gesting that EWI-2 is required for CD82 function [29]. It is not clear
how the CD82 interaction with EWI-2 affects the levels of
integrins.
The signaling pathways responsible for CD82 inhibition of cell
motility are not well understood. Overexpression of CD82 in
DU145 upregulates the expression of focal adhesion kinase (FAK)
and Lyn, a Src family tyrosine kinase [23]. The total amount of acti-
vated FAK and Lyn (as assessed by their phosphorylation), how-
ever, remains unchanged suggesting that their net activation is
impaired by CD82. The levels of p130CAS, a downstream target
of FAK-Lyn signaling, is also reduced by 2–4-fold. Consequently,
the coupling of phosphorylated p130CAS and CrkII required for cell
motility [30], is attenuated. The reduction in p130CAS is due to
post-transcriptional effects as the amount of RNA is not affected
[23]. Palmitoylation regulates CD82 localization and interaction
with other tetraspanins, suggesting that CD82 interactions in the
tetraspanin web are important for its motility-inhibitory effects.
Interestingly, palmitoylation is required for CD82 inhibition on
p130CAS–CrkII coupling [31]. The precise mechanism by which
CD82 lower the levels of p130CAS protein remains to be
discovered.
An important aspect of the function of CD82 in inhibiting cell
motility and invasion is by modulating the activity of receptor
tyrosine kinases (RTKs). CD82 has been reported to attenuate epi-
dermal growth factor receptor (EGFR) signaling by promoting
internalization of the activated receptor [32]. This might, in part,
be related to a CD82 endosomal–lysosomal sorting motif [33]
and its localization to endocytic vesicles and exosomes [34] (see
also below). The effect of CD82 on EGFR is inhibited by the gangli-
oside GD1a, which interferes with the ability of CD82 to recruit
EGFR into TEMs [35]. In a study from a different group, the capacity
of CD82 to inhibit EGFR appears to depend on PKC, Caveolin-1 and
the ganglioside GM3 [36]. In this model, EGFR internalization re-
sults from PKC phosphorylation of EGFR on Thr654. The effects of
CD82 on EGFR therefore depend on components of the TEM.
Another example of RTK regulation is provided by CD82 sup-
pression of c-Met [HGFR (hetatocyte growth factor receptor)] sig-
naling in the PC3 prostate cancer cell line [37]. In these cells,
CD82 reduces both integrin-dependent and HGF-induced activa-
tion of c-Met, although the levels of integrin are not altered.
CD82 inhibits cell motility by inhibiting signaling to c-Met and
Src, resulting in reduced activation of p130CAS [37]. In non-small
cell lung carcinoma, CD82 speciﬁcally inhibits HGF-induced lamel-
lipodial protrusion and cell migration but not HGF-induced prolif-
eration [38], providing a potential explanation for the lack of effect
of CD82 on primary tumor growth. CD82 does not interact directly
with c-Met; instead, CD82 interferes with the recruitment of adap-
tor proteins Grb2 and p85 to selectively attenuate c-Met signaling
via the Cdc42/Rac pathways. In contrast, c-Met mediated growthsignaling via AKT and MAPK is unaffected [38]. How CD82 reduces
Grb2 and p85 recruitment to c-Met is not known. As in the case for
EGFR, gangliosides also affect CD82 suppression of c-Met signaling.
In bladder cancer YTS1 cells, which do not express CD82, c-Met is
constitutively activated. Transfection of CD82 inhibits c-Met sig-
naling in the presence of GM2, indicating that the composition of
gangliosides in the complex can regulate CD82 activity on RTKs
and integrins [27].
A yeast two-hybrid screen identiﬁed Vangl1/Kitenin as a CD82-
interacting protein [26] that binds to the C-terminus of CD82.
Overexpression of Vangl1 in murine colon carcinoma cell line CT-
26 enhances tumorigenicity and metastasis in vivo, as well as in-
creases adhesion leading to invasion in vitro [26]. Interestingly,
overexpression of Vangl1 restores invasiveness of CT-26 cells
expressing CD82, suggesting that Vangl1 functions downstream
of CD82. Vangl1 was identiﬁed in a separate screen for proteins
phosphorylated in response to intestinal trefoil factor (ITF/TFF3),
which protects intestinal epithelia by promoting migration of epi-
thelial cells during mucosal repair [39]. Consistent with its pro-
migratory role, Vangl1 overexpression enhances wound closure
of intestinal epithelial cells, whereas siRNA directed against Vangl1
inhibited the migratory response to ITF. ITF stimulates phosphory-
lation of Vangl1 and promotes its dissociation from E-cadherin at
the plasma membrane. How CD82 regulates Vang1 is not clear.
An inverse relationship is reported for levels of Vangl1 and CD82
in CT-26 cells. Notably, expression of a splice variant of CD82 lack-
ing the C-terminus results in higher levels of Vangl1 [26]. One pos-
sible model for CD82 function is to regulate the trafﬁcking and
levels of Vangl1 by promoting its co-internalization.
Metastasis requires not only cell motility but also activation of
extracellular proteases that degrade the extracellular matrix and
facilitate cell invasion. Expression of CD82 results in a 50-fold de-
crease in urokinase plasminogen activator surface receptor (uPAR)
activity [40]. CD82 does not interact with uPAR directly. Instead,
CD82 causes a redistribution of uPAR to focal adhesions, where it
interacts with a5b1 integrin. This stable association with a5b1 pre-
vents uPAR binding to its ligand uPA, resulting in reduced extracel-
lular matrix proteolysis. CD82 can therefore regulate cell invasion
by regulating the localization of extracellular proteases.
These studies suggest that CD82 suppresses cell migration and
invasion by regulating the trafﬁcking of signaling proteins. How
CD82 achieves this through the tetraspanin web is not clear. Other
tetraspanins have been shown to affect the biosynthesis and traf-
ﬁcking of their associated proteins [41]. CD82 can also inhibit
receptor tyrosine kinases and integrin signaling by promoting their
internalization. These dynamic interactions appear to impact cell
motility and invasion by selectively targeting uPAR, Rho, PKC and
Src pathways.
3.3. Cell death and survival
The most critical step(s) in the metastatic cascade regulated by
CD82 is not known. While CD82 regulation of cell adhesion and
migration are well established, it is clear that CD82 has additional
functions in metastasis suppression. CD82 suppresses metastasis
of tumor cells delivered by intravenous injection suggesting that
CD82 functions are not limited to the primary tumor site. Further-
more, cells expressing elevated levels of CD82 do not show evi-
dence of defects in their extravasation into the lungs when
delivered by tail vein injection [8], suggesting that CD82 does not
prevent movement out of the vasculature into distant sites (i.e.
sites of potential metastases).
A major limiting factor in metastatic colonization is the survival
and proliferation of tumor cells at the distant site. As tumor cells
leave the primary tumor site, loss of adhesion can induce apoptosis
(anoikis) in circulating tumor cells. Studies using the HT1080
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lated post-translationally by proteasomal degradation after being
targeted by the ubiquitin ligase gp78 [8]. HT1080 cells in which
CD82 levels are elevated by loss of gp78 show an increase in apop-
tosis in the lung shortly after being injected into the tail vein of
mice [8]. This increased apoptosis results in a higher rate of tumor
cell attrition during early metastasis. In contrast, primary tumors
of gp78-deﬁcient cells do not show signs of increased apoptosis,
consistent with metastasis suppression by CD82. These results sug-
gest that CD82-dependent apoptosis depends on the tumor cell
interaction with the micro-environment.
ER stress and oxidative stress signaling have been implicated in
cancer progression. Both signaling pathways are coordinately reg-
ulated in cells. Cells activate a survival response called the un-
folded protein response (UPR) during ER stress (reviewed in
[42]). gp78 functions as a critical ubiquitin ligase in ER-associated
degradation (ERAD), an important part of the UPR. Sustained ER
stress activates cell death pathways possibly by accumulation of
reactive oxygen species (ROS). The mitochondrion is a major
source of ROS in cells. In addition, the ER also generates substantial
ROS during oxidative folding of proteins involving disulﬁde bond
formation. In the primary tumor, hypoxia upregulates survival
pathways and suppresses mitochondrial function to reduce the
accumulation of ROS, which may partially protect tumor cells from
the apoptotic effect of CD82. Hypoxia also upregulates autophagy;
increased autophagy appears to protect prostate cancer cells from
apoptosis [43], providing another explanation for the lack of effect
of CD82 on the primary tumor.
CD82 has also been shown to induce cell death in other studies
[15,44,45]. The mechanisms of cell death may involve ER stress and
autophagy [45] or oxidative stress associated with efﬂux of cellular
glutathione [44]. However, it is not clear whether loss of intracel-
lular glutathione is the cause or result of apoptosis [44]. The mul-
tidrug resistance protein MRP1, when properly localized to the
plasma membrane, appears to mediate the efﬂux of cellular gluta-
thione during apoptosis [46]. The effect of CD82 on the maturation
or localization of MRP1 has not been studied. Overexpression of
CD82 induces autophagic cell death in multiple myeloma cells
[45] but only when it is GFP-tagged on the C-terminus [47]. In con-
trast, overexpression of N-terminal tagged CD82 inhibits cellular
adhesion and migration but does not induce cell death. N-terminal
tagged CD82 localizes to the plasma membrane of multiple myelo-
ma cells, whereas C-terminal tagged CD82 accumulates inside the
cell reminiscent of intracellular inclusions [47]. These results sug-
gest that cell death observed in [47] is likely caused by protein mis-
folding or improper trafﬁcking of the overexpressed C-terminal
tagged CD82 in multiple myeloma cells, which are sensitive to ER
stress.
3.4. Tumor cell senescence
The blood group Duffy antigen receptor for chemokines (DARC)
has been identiﬁed as a CD82-interacting protein [7]. DARC is ex-
pressed on the surface of erythrocytes and endothelial cells. Tumor
cells expressing CD82 show enhanced adhesion to endothelial
cells. The interaction of CD82 and DARC induces cellular senes-
cence in the tumor cells in vitro, providing a possible explanation
for the inhibitory effect of CD82 on metastasis, although tumor cell
senescence in CD82-mediated metastasis suppression was not as-
sessed in vivo [7]. Furthermore, the ability of CD82 to suppress
metastasis of B16 melanoma cells is signiﬁcantly compromised in
DARC knockout mice, providing additional evidence that DARC
may play a role in CD82-mediated metastasis suppression.
This provocative study provides insights into how CD82 specif-
ically suppresses metastasis without inhibiting primary tumor
growth. As tumor cells in the primary tumor do not contact DARC,which is highly expressed in cells of the vasculature, the presence
of CD82 does not affect their proliferation. However, several issues
remain unanswered. It is not known how CD82–DARC interaction
induces tumor cell senescence. Moreover, sarcoma cells with ele-
vated levels of CD82 do not show signs of senescence when cul-
tured with endothelial cells [8], suggesting that the senescence
signal is cell-type speciﬁc. Furthermore, the signiﬁcance of
CD82–DARC interaction induced senescence in metastasis sup-
pression in vivo is not clear. Although tumor cells show increased
metastasis in DARC/ mice [7], the inability of CD82 to suppress
metastasis in DARC-deﬁcient mice could be related to increased
angiogenesis in these animals [48,49]. DARC-deﬁcient endothelial
cells show enhanced angiogenesis in vitro as these cells escape
senescence induced by DARC [49]. DARC has also been shown to
remove angiogenic chemokines secreted by tumor cells [48]. Con-
sequently, DARC-deﬁcient mice show increased prostate tumor
growth due to accumulation of angiogenic chemokines and in-
creased angiogenesis [48]. Based on results from DARC-deﬁcient
mice, a role for DARC in prostate tumor progression has been pos-
tulated for African men as 70% of this population exhibit loss of
DARC expression in erythrocytes [48]. However, a recent study
ﬁnds little or no association between erythrocyte DARC expression
and the risk or progression of prostate cancer in men of African
descent [50]. Further study is clearly needed to address these
questions.
3.5. Exosomes
Exosomes are small vesicles that are derived from the multive-
sicular body and released into the extracellular space upon fusion
with the plasmamembrane (reviewed in [51]). Exosomes can serve
to transfer both genetic materials and proteins to distant cells.
Interestingly these structures are enriched in tetraspanins includ-
ing CD82 [34].
Highly provocative ﬁndings on a potential role for CD82 acting
as a metastasis suppressor through exosome formation comes
from a study on the Wnt signaling pathway. The Wnt signaling
pathway, which is mediated in part through b-catenin and down-
stream effectors, is implicated in cell growth and metastasis.
CD82 as well as CD9, another tetraspanin, suppress b-catenin-med-
iated Wnt signaling activity and induce a signiﬁcant decrease in b-
catenin levels [52]. This decrease occurs by induction of b-catenin
export via exosomes, which can be blocked by a sphingomyelinase
inhibitor. CD82 fails to induce exosome release of b-catenin in cells
that express low levels of E-cadherin. These results suggest that
CD82 and CD9 down-regulate the Wnt signaling pathway through
the exosomal clearance of b-catenin. This is interesting in light of
the ﬁnding that a b-catenin/Reptin complex represses CD82 tran-
scription [53]. These results suggest the existence of a feed forward
mechanism whereby an increase in b-catenin inhibits CD82
expression to further enhance Wnt signaling. The signiﬁcance of
this pathway to CD82 metastasis suppression remains to be deter-
mined. Conversely, exosomal removal of b-catenin could relieve
repression of CD82 expression by b-catenin, possibly leading to
further increase in exosome release and attenuation of Wnt
signaling.4. Regulation of CD82 expression
A challenge to activating CD82 for therapy requires an under-
standing of how CD82 is regulated in normal and cancerous tis-
sues. There is little evidence for gene mutation or loss of
heterozygosity, promoter mutation or promoter hypermethylation
to account for loss of CD82 expression [54–58]. Loss of CD82 dur-
ing cancer progression may result from changes in transcriptional
3170 Y.C. Tsai, A.M. Weissman / FEBS Letters 585 (2011) 3166–3173regulation in tumor cells. An alternatively spliced variant of CD82,
which produces a dominant negative protein, has also been de-
scribed. More recently, post-translational modiﬁcation has been
shown to play a role in regulating the levels of CD82 in tumor cells.
4.1. Transcriptional regulation
Three regulatory regions have been deﬁned in the human CD82
promoter: an enhancer region, a negative regulatory region and a
minimal promoter region [59,60]. Expression of CD82 can be in-
duced with cytokines, growth factors, phorbol esters and drugs
[61–65]. A p53 regulatory element has been described in the en-
hancer region [62]. However, several studies correlating p53 loss
and CD82 expression do not support a simple model for CD82 reg-
ulation [66,67]. One way to reconcile these differences is provided
by the ﬁnding that CD82 expression is regulated by p53, JunB and
AP2 as described in [60,68]. Furthermore, JunB induction of CD82
expression can be enhanced by ATF3 [69]. The requirement for
more than one transcription factor at the promoter may explain
the contradictory data concerning the role of p53 in regulating
CD82 expression [62,66,70,71].
CD82 expression by NF-jB is induced by pro-inﬂammatory
cytokines such as IL-1b, IL-4, IL-6, IFN-c and TNF-a [72]. The
CD82 promoter has a binding site for NF-jB p50 subunit. In non-
metastatic cells, binding of p50 and a NCOR1–TAB2–HDAC3 co-
repressor complex inactivates transcription. IL-1b stimulation re-
cruits a Tip60/Fe65/Pontin co-activator complex that displaces
the NCOR1 complex [53]. In metastatic cells, Tip60 is downregu-
lated and a b-catenin/Reptin complex replaces the Tip60/Pontin
complex. Unlike Tip60/Pontin complex, the b-catenin/Reptin com-
plex represses NF-jB activation of CD82 expression [53]. The
repressor function of Reptin requires sumoylation on Lys456; a
Reptin mutant that lacks functional sumoylation relieves tran-
scriptional repression [73]. Similarly, overexpression of a de-













Fig. 2. Schematic of CD82 regulation and functions. CD82 can be transcriptionally activ
regulated by the alternative recruitment of Tip60/Pontin or b-catenin/Reptin complex. In
shown), which is displaced by a Tip60/Pontin co-activator complex for p50 in the presenc
Reptin complex, which represses CD82 transcription. Sumoylation of Reptin is required f
repress p50 induction of CD82. After translation (above), CD82 protein is regulated by qu
associated degradation (ERAD), depends on the ubiquitin ligase gp78. In some cancer
accelerating its degradation from the ER. CD82 inhibits metastasis by multiple mechani
tumor cell senescence and enhancing exosomal discharge of b-catenin.Reptin [73]. These data provide a direct link for Reptin post-trans-
lational modiﬁcation by sumoylation to cancer metastasis.
Recent studies suggest that hypoxia induces CD82 expression
[74]. A hypoxia-response element is identiﬁed within the 500 bp
upstream region of mouse CD82 gene. Hypoxia-dependent induc-
tion of CD82 is mediated by hypoxia-inducible factor (HIF)-1a,
which binds to the CD82 promoter. Consistent with this hypothe-
sis, hypoxia-driven upregulation of CD82 is abrogated in HIF-1a
null mouse embryonic ﬁbroblasts. Ischemic tissues show increased
CD82 protein synthesis suggesting that CD82 is a hypoxia target
gene in vivo. Hypoxia also can induce CD82 expression indirectly.
Hypoxia induces the expression of another metastasis suppressor,
NDRG1 [75]. NDRG1 inhibits metastasis partly by downregulating
the expression of the transcription factor ATF3 [76], which inter-
acts with NF-jB p50 to repress CD82 expression [69].
CD82 transcription can also be regulated epigenetically [77].
This is exempliﬁed by the Special AT-rich sequence-binding pro-
tein 1 (SATB1), which recruits chromatin remodeling enzymes to
regulate chromatin structure and gene expression. SATB1 down-
regulates the transcription of CD82, as well as other metastasis
suppressor genes, through chromatin modiﬁcation. RNAi-mediated
knockdown of SATB1 in the highly aggressive breast cancer cell
line MDA-MB-231 strikingly restores breast-like acinar polarity
and inhibits tumor growth and metastasis in vivo. On the other
hand, ectopic overexpression of SATB1 increases the metastatic po-
tential of the relatively non-aggressive breast cancer cell line
SKBR3 [77].
4.2. Post-translational regulation
Besides transcription, the levels of CD82 can also be regulated
by post-translational modiﬁcations. CD82 undergoes modiﬁcation
of its N-linked glycans in the secretory pathways and is subject
to endoplasmic reticulum quality control mechanisms [78]. The















ated by p53, JunB, AP2, NF-jB p50 and HIF-1 (below). CD82 expression by p50 is
normal cells, CD82 transcription is repressed by a NCOR/TAB2/HDAC3 complex (not
e of cytokines. In cancer cells, Tip60 is downregulated and replaced with a b-catenin/
or its repressor function, which can be inactivated by de-sumoylation. ATF3 can also
ality control mechanisms in the endoplasmic reticulum. This process, known as ER-
cells, cAMP promotes CD82 degradation either by enhancing its internalization or
sms, including inhibiting cell motility and invasion, promoting apoptosis, inducing
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reticulum-associated degradation (ERAD) [79]. RNAi-mediated
knockdown of gp78 inhibits sarcoma metastasis but not primary
tumor growth, an effect that mirrors overexpression of metastasis
suppressors [8]. Loss of gp78 accumulates CD82 due to reduced
degradation of the metastasis suppressor. Consistent with this
idea, the metastatic activity of gp78 requires its ubiquitin ligase
activity [8] but not its putative function as the human autocrine
motility factor (AMF; phosphoglucose isomerase) receptor (AMFR),
which was proposed [80,81] prior to its characterization as a ubiq-
uitin ligase involved in ERAD [82]. gp78 promotes the degradation
of CD82, improving cell viability during metastasis. Furthermore,
levels of CD82 correlate inversely with gp78 in a sample of sarco-
mas [8]. The study of metastasis suppressors has relied on their
overexpression in cells that normally lack expression of the genes.
Although a powerful approach, overexpression studies sometimes
raise questions about the function of the endogenous protein. This
study in sarcoma cells [8] provides direct evidence that raising the
levels of endogenous CD82, by preventing its ubiquitination and
proteasomal degradation, suppresses metastasis but does not af-
fect primary tumor growth, conﬁrming the metastasis suppressor
function of CD82.
In a MMTV-gp78 transgenic mouse model, overexpression of
gp78 in mammary tissue results in selective loss of CD82 and
mammary gland hyperplasia [83], reinforcing the importance of
post-translational regulation of CD82 levels in vivo. These studies
in which gp78 levels are manipulated with resultant effects on
CD82 levels establish an important role for post-translational reg-
ulation of metastasis suppressors and provide an example of how
metastasis suppressor activity can be lost without loss of gene
expression [8,80]. The possibility of signiﬁcant post-translational
regulation of metastasis suppressor genes should also caution
against drawing conclusions based on studies that focus simply
on changes in gene transcription during metastasis.
Post-translational regulation of CD82 also plays a role in regu-
lating trophoblast invasion. Decidual cells show strong expression
of CD82 [63] and silencing of CD82 increases trophoblast invasion
[84]. In decidualizing endometrial stromal cells, CD82 is induced
by cAMP. Interestingly, induction of CD82 by cAMP analog results
not from increased gene transcription but rather increased CD82
protein stability. In contrast, the cAMP analog 8-bromo-cAMP in-
duces accelerated degradation of CD82 in breast cancer cells [63].
Understanding the changes in post-translational regulation of
CD82 in cancer cells may lead to new targets for activating CD82
in advanced stages of the disease.
Besides ubiquitination, CD82 is also regulated by palmitoylation
and glycosylation, both of which are required for CD82 function
[15,31]. It is tempting to speculate that loss of these post-transla-
tional modiﬁcations may directly, or indirectly promote CD82
clearance by the cellular quality control systems and thereby inac-
tivate the metastasis suppressor functions of CD82. A schematic of
CD82 regulation and functions in metastasis suppression is sum-
marized in Fig. 2.
5. Conclusion and future directions
CD82 suppresses metastasis at multiple steps of the metastatic
cascade. CD82 does not appear to have intrinsic enzymatic activity;
however, it has become clear in recent years that CD82 has an im-
pact on multiple signaling pathways by regulating the trafﬁcking of
partner proteins and by inﬂuencing cell membrane dynamics.
Although the role of CD82 on cell surface dynamics has been stud-
ied extensively, recent studies suggest that CD82 may play addi-
tional metastasis suppressor functions in the secretory pathway.
Despite these advances, much remains to be understood abouthow CD82 functions at a molecular level and how it suppresses
metastasis. Most studies to date have focused on the effect of over-
expressing CD82 on speciﬁc cell lines, measuring changes in prop-
erties such as cell motility, adhesion or senescence in vitro.
Whether these effects are important in vivo remain to be deter-
mined. Furthermore, it is not clear that results obtained in speciﬁc
cell lines can be generalized to other malignancies. Indeed it is pos-
sible that CD82 plays distinct roles in different cell types, possibly
explaining some of the contradictory ﬁndings in the ﬁeld. As we
gain a better understanding of CD82 function in normal and cancer
cells, some of these issues would hopefully be resolved. For efﬁ-
cient targeting of CD82 in therapy, it is important to learn about
the mechanisms by which CD82 changes during cancer progres-
sion, which could lead to novel methods of activating the metasta-
sis suppressor. Besides transcriptional changes, it is now clear that
CD82 is regulated by post-translational mechanisms. Changes in
post-transcriptional regulation of CD82 in metastatic cells may
well play a critical role in disease progression. It is also critical to
investigate the effects of activating CD82 during different stages
of cancer progression. This can be studied by regulating the expres-
sion of CD82 in animal models. Such experiments should also fur-
ther clarify the precise steps in metastasis regulated by CD82.
Finally, the relationship of CD82 to other metastasis suppressor
has not been studied. If signaling from CD82 overlaps with those
of other metastasis suppressors, novel targets can be identiﬁed
that provide a common node for treating metastasis.
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